Literature DB >> 21947230

Inhibition of the adenylyl cyclase toxin, edema factor, from Bacillus anthracis by a series of 18 mono- and bis-(M)ANT-substituted nucleoside 5'-triphosphates.

Hesham Taha1, Stefan Dove, Jens Geduhn, Burkhard König, Yuequan Shen, Wei-Jen Tang, Roland Seifert.   

Abstract

Bacillus anthracis causes anthrax disease and exerts its deleterious effects by the release of three exotoxins, i.e. lethal factor, protective antigen and edema factor (EF), a highly active calmodulin-dependent adenylyl cyclase (AC). Conventional antibiotic treatment is ineffective against either toxaemia or antibiotic-resistant strains. Thus, more effective drugs for anthrax treatment are needed. Our previous studies showed that EF is differentially inhibited by various purine and pyrimidine nucleotides modified with N-methylanthraniloyl (MANT)- or anthraniloyl (ANT) groups at the 2'(3')-O-ribosyl position, with the unique preference for the base cytosine (Taha et al., Mol Pharmacol 75:693 (2009)). MANT-CTP was the most potent EF inhibitor (K (i), 100 nM) among 16 compounds studied. Here, we examined the interaction of EF with a series of 18 2',3'-O-mono- and bis-(M)ANT-substituted nucleotides, recently shown to be very potent inhibitors of the AC toxin from Bordetella pertussis, CyaA (Geduhn et al., J Pharmacol Exp Ther 336:104 (2011)). We analysed purified EF and EF mutants in radiometric AC assays and in fluorescence spectroscopy studies and conducted molecular modelling studies. Bis-MANT nucleotides inhibited EF competitively. Propyl-ANT-ATP was the most potent EF inhibitor (K (i), 80 nM). In contrast to the observations made for CyaA, introduction of a second (M)ANT-group decreased rather than increased inhibitor potency at EF. Activation of EF by calmodulin resulted in effective fluorescence resonance energy transfer (FRET) from tryptophan and tyrosine residues located in the vicinity of the catalytic site to bis-MANT-ATP, but FRET to bis-MANT-CTP was only small. Mutations N583Q, K353A and K353R differentially altered the inhibitory potencies of bis-MANT-ATP and bis-MANT-CTP. The nucleotide binding site of EF accommodates bulky bis-(M)ANT-substituted purine and pyrimidine nucleotides, but the fit is suboptimal compared to CyaA. These data provide a basis for future studies aiming at the development of potent EF inhibitors with high selectivity relative to mammalian ACs.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21947230     DOI: 10.1007/s00210-011-0688-9

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  27 in total

Review 1.  Bioterriorism: from threat to reality.

Authors:  Ronald M Atlas
Journal:  Annu Rev Microbiol       Date:  2002-01-30       Impact factor: 15.500

2.  A conformational transition in the adenylyl cyclase catalytic site yields different binding modes for ribosyl-modified and unmodified nucleotide inhibitors.

Authors:  Jenna L Wang; Jian-Xin Guo; Qi-Yuan Zhang; Jay J-Q Wu; Roland Seifert; Gerald H Lushington
Journal:  Bioorg Med Chem       Date:  2007-02-11       Impact factor: 3.641

3.  Calcium-independent calmodulin binding and two-metal-ion catalytic mechanism of anthrax edema factor.

Authors:  Yuequan Shen; Natalia L Zhukovskaya; Qing Guo; Jan Florián; Wei-Jen Tang
Journal:  EMBO J       Date:  2005-02-17       Impact factor: 11.598

Review 4.  The adenylyl cyclase activity of anthrax edema factor.

Authors:  Wei-Jen Tang; Qing Guo
Journal:  Mol Aspects Med       Date:  2009-06-26

5.  Structural basis for the inhibition of mammalian membrane adenylyl cyclase by 2 '(3')-O-(N-Methylanthraniloyl)-guanosine 5 '-triphosphate.

Authors:  Tung-Chung Mou; Andreas Gille; David A Fancy; Roland Seifert; Stephen R Sprang
Journal:  J Biol Chem       Date:  2004-12-09       Impact factor: 5.157

6.  Differential interactions of G-proteins and adenylyl cyclase with nucleoside 5'-triphosphates, nucleoside 5'-[gamma-thio]triphosphates and nucleoside 5'-[beta,gamma-imido]triphosphates.

Authors:  Andreas Gille; Jianxin Guo; Tung-Chung Mou; Michael B Doughty; Gerald H Lushington; Roland Seifert
Journal:  Biochem Pharmacol       Date:  2005-11-04       Impact factor: 5.858

7.  Broad specificity of mammalian adenylyl cyclase for interaction with 2',3'-substituted purine- and pyrimidine nucleotide inhibitors.

Authors:  Tung-Chung Mou; Andreas Gille; Srividya Suryanarayana; Mark Richter; Roland Seifert; Stephen R Sprang
Journal:  Mol Pharmacol       Date:  2006-06-09       Impact factor: 4.436

8.  Role of toxin functional domains in anthrax pathogenesis.

Authors:  F Brossier; M Weber-Levy; M Mock; J C Sirard
Journal:  Infect Immun       Date:  2000-04       Impact factor: 3.441

Review 9.  The structure and function of novel proteins of Bacillus anthracis and other spore-forming bacteria: development of novel prophylactic and therapeutic agents.

Authors:  Mark J Jedrzejas
Journal:  Crit Rev Biochem Mol Biol       Date:  2002       Impact factor: 8.250

10.  Molecular analysis of the interaction of Bordetella pertussis adenylyl cyclase with fluorescent nucleotides.

Authors:  Martin Göttle; Stefan Dove; Phillip Steindel; Yuequan Shen; Wei-Jen Tang; Jens Geduhn; Burkhard König; Roland Seifert
Journal:  Mol Pharmacol       Date:  2007-06-06       Impact factor: 4.436

View more
  9 in total

Review 1.  Designing inhibitors of anthrax toxin.

Authors:  Ekaterina M Nestorovich; Sergey M Bezrukov
Journal:  Expert Opin Drug Discov       Date:  2014-01-22       Impact factor: 6.098

Review 2.  An overview of investigational toxin-directed therapies for the adjunctive management of Bacillus anthracis infection and sepsis.

Authors:  Lernik Ohanjanian; Kenneth E Remy; Yan Li; Xizhong Cui; Peter Q Eichacker
Journal:  Expert Opin Investig Drugs       Date:  2015-04-28       Impact factor: 6.206

Review 3.  Inhibitors of membranous adenylyl cyclases.

Authors:  Roland Seifert; Gerald H Lushington; Tung-Chung Mou; Andreas Gille; Stephen R Sprang
Journal:  Trends Pharmacol Sci       Date:  2011-11-17       Impact factor: 14.819

Review 4.  Molecular motions as a drug target: mechanistic simulations of anthrax toxin edema factor function led to the discovery of novel allosteric inhibitors.

Authors:  Elodie Laine; Leandro Martínez; Daniel Ladant; Thérèse Malliavin; Arnaud Blondel
Journal:  Toxins (Basel)       Date:  2012-07-31       Impact factor: 4.546

5.  Acyclic nucleoside phosphonates with 2-aminothiazole base as inhibitors of bacterial and mammalian adenylate cyclases.

Authors:  Petra Břehová; Ema Chaloupecká; Michal Česnek; Jan Skácel; Martin Dračínský; Eva Tloušťová; Helena Mertlíková-Kaiserová; Monica P Soto-Velasquez; Val J Watts; Zlatko Janeba
Journal:  Eur J Med Chem       Date:  2021-05-28       Impact factor: 7.088

Review 6.  Structural Biology and Molecular Modeling to Analyze the Entry of Bacterial Toxins and Virulence Factors into Host Cells.

Authors:  Irène Pitard; Thérèse E Malliavin
Journal:  Toxins (Basel)       Date:  2019-06-24       Impact factor: 4.546

7.  Analyzing In Silico the Relationship Between the Activation of the Edema Factor and Its Interaction With Calmodulin.

Authors:  Irène Pitard; Damien Monet; Pierre L Goossens; Arnaud Blondel; Thérèse E Malliavin
Journal:  Front Mol Biosci       Date:  2020-12-04

Review 8.  Bacillus anthracis edema factor substrate specificity: evidence for new modes of action.

Authors:  Martin Göttle; Stefan Dove; Roland Seifert
Journal:  Toxins (Basel)       Date:  2012-07-06       Impact factor: 4.546

Review 9.  Pharmacophore selection and redesign of non-nucleotide inhibitors of anthrax edema factor.

Authors:  Catherine H Schein; Deliang Chen; Lili Ma; John J Kanalas; Jian Gao; Maria Estrella Jimenez; Laurie E Sower; Mary A Walter; Scott R Gilbertson; Johnny W Peterson
Journal:  Toxins (Basel)       Date:  2012-11-08       Impact factor: 4.546

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.